Credit Suisse Group Reiterates “Neutral” Rating for AstraZeneca plc (AZN)

Credit Suisse Group reissued their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Monday morning, MarketBeat Ratings reports. The brokerage currently has a GBX 5,000 ($63.70) target price on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. Deutsche Bank AG cut their price target on AstraZeneca plc from GBX 5,500 ($70.07) to GBX 5,350 ($68.16) and set a buy rating on the stock in a report on Friday, April 28th. Barclays PLC reiterated an overweight rating and issued a GBX 6,000 ($76.44) price target on shares of AstraZeneca plc in a report on Monday, March 27th. Societe Generale reiterated a buy rating on shares of AstraZeneca plc in a report on Thursday, March 23rd. HSBC Holdings plc cut AstraZeneca plc to a reduce rating and set a GBX 4,500 ($57.33) price objective for the company. in a research report on Friday, April 7th. Finally, Jefferies Group LLC cut AstraZeneca plc from a buy rating to a hold rating and lowered their price objective for the stock from GBX 5,350 ($68.16) to GBX 5,050 ($64.34) in a research report on Monday, April 10th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of GBX 5,171.80 ($65.89).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (AZN) opened at 5440.00 on Monday. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s 50 day moving average price is GBX 5,134.14 and its 200-day moving average price is GBX 4,718.55. The company’s market capitalization is GBX 68.87 billion.

TRADEMARK VIOLATION WARNING: This news story was published by Mideast Time and is owned by of Mideast Time. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.mideasttime.com/credit-suisse-group-reiterates-neutral-rating-for-astrazeneca-plc-azn/1804124.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:AZN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.